Enanta Pharmaceuticals
ENTA
137 hedge funds and large institutions have $483M invested in Enanta Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 50 increasing their positions, 42 reducing their positions, and 28 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
19% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 42
2.34% less ownership
Funds ownership: 79.62% → 77.29% (-2.3%)
6% less funds holding
Funds holding: 145 → 137 (-8)
13% less capital inflows, than outflows
Capital inflows: $83.3M | Capital outflows: $95.8M
21% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 28
88% less call options, than puts
Call options by funds: $1.02M | Put options by funds: $8.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
+$16.4M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
+$6.85M |
| 3 |
SAM
Senzar Asset Management
New York
|
+$5.34M |
| 4 |
Aureus Asset Management
Boston,
Massachusetts
|
+$5.09M |
| 5 |
Krensavage Asset Management
New York
|
+$4.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Consonance Capital Management
New York
|
-$20.6M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
-$13M |
| 3 |
Gotham Asset Management
New York
|
-$11.3M |
| 4 |
State Street
Boston,
Massachusetts
|
-$10.1M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.98M |
ENTA Hedge Fund Activity: Q4 2015 in Review
137 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2015, worth a combined $483M — down 11% from $541M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ENTA and 22 opened new positions — a net loss of 6 holders — while 42 trimmed existing stakes and 50 added.
The largest buyer was OrbiMed, opening a new position worth an estimated $16.4M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $20.6M sold.
- 137 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2015, down from 145 in Q3 2015.
- Funds reported $483M of Enanta Pharmaceuticals stock for Q4 2015, down 11% quarter-over-quarter.
- 22 funds opened new Enanta Pharmaceuticals positions in Q4 2015 and 28 closed out, a net change of -6 holders.
- The largest Enanta Pharmaceuticals buyer in Q4 2015 was OrbiMed, an estimated $16.4M added.
- The largest Enanta Pharmaceuticals seller in Q4 2015 was Consonance Capital Management, an estimated $20.6M sold.
Based on aggregated 13F filings for Q4 2015.